845 related articles for article (PubMed ID: 19126669)
1. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
[TBL] [Abstract][Full Text] [Related]
2. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
[TBL] [Abstract][Full Text] [Related]
3. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
[TBL] [Abstract][Full Text] [Related]
5. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
[TBL] [Abstract][Full Text] [Related]
6. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
Trecarichi EM; Tumbarello M; Spanu T; Caira M; Fianchi L; Chiusolo P; Fadda G; Leone G; Cauda R; Pagano L
J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
[TBL] [Abstract][Full Text] [Related]
7. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
8. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
[TBL] [Abstract][Full Text] [Related]
11. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
[TBL] [Abstract][Full Text] [Related]
12. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
14. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; Cueto Md; Gálvez J; Perea EJ; Pascual A
Clin Microbiol Infect; 2008 Feb; 14(2):180-3. PubMed ID: 18005358
[TBL] [Abstract][Full Text] [Related]
15. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
[TBL] [Abstract][Full Text] [Related]
16. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli.
Rooney PJ; O'Leary MC; Loughrey AC; McCalmont M; Smyth B; Donaghy P; Badri M; Woodford N; Karisik E; Livermore DM
J Antimicrob Chemother; 2009 Sep; 64(3):635-41. PubMed ID: 19549667
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Kang CI; Song JH; Chung DR; Peck KR; Ko KS; Yeom JS; Ki HK; Son JS; Lee SS; Kim YS; Jung SI; Kim SW; Chang HH; Ryu SY; Kwon KT; Lee H; Moon C; Shin SY;
Int J Antimicrob Agents; 2010 Sep; 36(3):284-7. PubMed ID: 20580534
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control.
Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; Perea EJ; Pérez-Cano R; Hernández JR; Pascual A
Clin Infect Dis; 2006 Jan; 42(1):37-45. PubMed ID: 16323089
[TBL] [Abstract][Full Text] [Related]
19. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lautenbach E; Strom BL; Bilker WB; Patel JB; Edelstein PH; Fishman NO
Clin Infect Dis; 2001 Oct; 33(8):1288-94. PubMed ID: 11565067
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection.
van der Starre WE; van Nieuwkoop C; Paltansing S; van't Wout JW; Groeneveld GH; Becker MJ; Koster T; Wattel-Louis GH; Delfos NM; Ablij HC; Leyten EM; Blom JW; van Dissel JT
J Antimicrob Chemother; 2011 Mar; 66(3):650-6. PubMed ID: 21123286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
